drugset / Trial / NCT05056402
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
Phase 3
Active not recruiting
1382 enrolled
Xiamen University
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. · collabXiamen Innovax Biotech Co., Ltd · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This is a open label clinical trial to evaluate the safety and immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., in healthy population aged 9-17 years old in comparison with aged 18-26.
Timeline
- Start
- 2021-09-19
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli) | Vaccine | 270 ug | Intramuscular |